Determination of amosulalol in human plasma using solid-phase extraction combined with liquid chromatography and ultraviolet detection

J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Apr 25;818(2):109-13. doi: 10.1016/j.jchromb.2004.06.029.


Amosulalol is an antihypertensive drug with selective postsynaptic alpha 1 and non-selective beta blocking effects. A simple solid-phase extraction and high-performance liquid chromatographic (HPLC) method has been developed and validated for the quantitative determination of amosulalol in human plasma. A reversed phase C18 column was used for the separation of amosulalol and ethyl paraben (internal standard) with a mobile phase composed of 0.025 M phosphate buffer (pH 6.0).acetonitrile (73:27, v/v) at a flow rate of 1.5 mL/min. The ultraviolet detector was operated at the 272 nm wavelength. Intra- and inter-day precision and accuracy were acceptable for all quality control samples including the lower limit of quantification of 30 ng/mL. Recovery of amosulalol from human plasma was >95.6%. Amosulalol was stable in human plasma under various storage conditions. This method was used successfully for a pharmacokinetic study in plasma after oral administration of a single 20 mg dose of amosulalol hydrochloride to 16 healthy volunteers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antihypertensive Agents / blood*
  • Antihypertensive Agents / isolation & purification
  • Antihypertensive Agents / pharmacokinetics
  • Chromatography, High Pressure Liquid / methods*
  • Ethanolamines / blood*
  • Ethanolamines / isolation & purification
  • Ethanolamines / pharmacokinetics
  • Female
  • Humans
  • Male
  • Reproducibility of Results
  • Sensitivity and Specificity


  • Antihypertensive Agents
  • Ethanolamines
  • amosulalol